

Jesus Yamamoto-Furusho

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4907898/jesus-yamamoto-furusho-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

2,579
citations

27
h-index

44
g-index

154
ext. papers

2,993
ext. citations

3.4
avg, IF

5.36
L-index

#	Paper	IF	Citations
131	Association of dietary fiber consumption with disease activity in ulcerative colitis: An exploratory study in the Mexican population.. <i>Gaceta Medica De Mexico</i> , 2022 , 158, 41-47	0.3	0
130	Mental Health Factors Associated With Fatigue in Mexican Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 609-614	3	0
129	Depression and Anxiety Disorders Impact in the Quality of Life of Patients with Inflammatory Bowel Disease. <i>Psychiatry Journal</i> , 2021 , 2021, 5540786	2.4	0
128	Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021 , 44, 206-213	0.1	0
127	Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 206-213	0.9	1
126	Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 711-718	0.9	1
125	Intestinal production of secreted protein acidic and rich in cysteine (SPARC) in patients with ulcerative colitis. <i>Immunobiology</i> , 2021 , 226, 152095	3.4	0
124	Gene expression profiling of inflammatory cytokines in esophageal biopsies of different phenotypes of gastroesophageal reflux disease: a cross-sectional study. <i>BMC Gastroenterology</i> , 2021 , 21, 201	3	7
123	AKAP12/Gravin is over-expressed in patients with ulcerative colitis. <i>Immunologic Research</i> , 2021 , 69, 429-435	4.3	0
122	Expression of TOB/BTG family members in patients with inflammatory bowel disease. <i>Scandinavian Journal of Immunology</i> , 2021 , 93, e13004	3.4	5
121	Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: Cross-sectional study. <i>Scandinavian Journal of Immunology</i> , 2021 , 93, e12962	3.4	5
120	Changes in chronic idiopathic ulcerative colitis epidemiological pattern in Mexico in a tertiary care hospital. <i>Gaceta Medica De Mexico</i> , 2021 , 157, 147-153	0.3	0
119	ABCC7/CFTR Expression Is Associated with the Clinical Course of Ulcerative Colitis Patients. <i>Gastroenterology Research and Practice</i> , 2021 , 2021, 5536563	2	1
118	Differential Cytokine Expression in the Duodenum and Rectum of Children with Non-Immunoglobulin E-Mediated Cow Milk Protein Allergy. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3769-3775	4	1
117	Emerging therapeutic options in inflammatory bowel disease.. <i>World Journal of Gastroenterology</i> , 2021 , 27, 8242-8261	5.6	1
116	Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021 , 44, 711-718	0.1	0
115	Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country. <i>Inflammatory Intestinal Diseases</i> , 2020 , 5, 200-204	2.5	0

114	TRPV Subfamily (TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6) Gene and Protein Expression in Patients with Ulcerative Colitis. <i>Journal of Immunology Research</i> , 2020 , 2020, 2906845	4.5	8
113	Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study. <i>Digestive and Liver Disease</i> , 2020 , 52, 869-877	3.3	5
112	Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2020 , 2020, 9238970	4.3	11
111	Mortality and Hospitalizations in Mexican Patients with Inflammatory Bowel Disease: Results from a Nationwide Health Registry. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020 , 2020, 8825330	3.8	3
110	Synthesis of Interleukin-10 in Patients with Ulcerative Colitis and Infection. <i>Gastroenterology Research and Practice</i> , 2020 , 2020, 4171083	2	0
109	Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis. <i>Gastroenterology Research and Practice</i> , 2020 , 2020, 8891937	2	1
108	Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2020 , 15, e0231988	3.7	6
107	Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells. <i>Cellular Signalling</i> , 2020 , 72, 109636	4.9	25
106	Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. <i>Revista De Gastroenterología De México</i> , 2019 , 84, 317-325	0.7	7
105	Validación de Belief Medicines Questionnaire y Self-efficacy for Appropriate Medication Use Scale para medir adherencia al tratamiento farmacológico en pacientes con enfermedad inflamatoria intestinal. <i>Gaceta Medica De Mexico</i> , 2019 , 155, 124-129	0.3	
104	Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017). <i>Medicine (United States)</i> , 2019 , 98, e16291	1.8	23
103	Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease. <i>Revista De Gastroenterología De México</i> , 2019 , 84, 11-17	0.7	1
102	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. <i>Revista De Gastroenterología De México</i> , 2018 , 83, 144-167	0.7	14
101	Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico. <i>Revista De Gastroenterología De México</i> , 2018 , 83, 414-423	0.7	3
100	Joint involvement in Mexican patients with ulcerative colitis: a hospital-based retrospective study. <i>Clinical Rheumatology</i> , 2018 , 37, 677-682	3.9	5
99	Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. <i>Journal of Inflammation</i> , 2018 , 15, 13	6.7	10
98	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , 2018 , 16, 522-528	4.1	11
97	Differential Expression of IL-36 Family Members and IL-38 by Immune and Nonimmune Cells in Patients with Active Inflammatory Bowel Disease. <i>BioMed Research International</i> , 2018 , 2018, 5140691	3	35

96	Hospital Anxiety and Depression Scale (HADS): Validation in Mexican Patients with Inflammatory Bowel Disease. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 477-482	0.9	13
95	Hospital Anxiety and Depression Scale (HADS): Validation in Mexican patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 477-482	0.1	2
94	The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2018 , 2018, 6570371	4.3	7
93	Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways. <i>Current Opinion in Gastroenterology</i> , 2018 , 34, 187-193	3	30
92	The Mexican consensus on probiotics in gastroenterology. <i>Revista De Gastroenterología De México</i> , 2017 , 82, 156-178	0.7	17
91	Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). <i>Revista De Gastroenterología De México</i> , 2017 , 82, 134-155	0.7	2
90	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterología De México</i> , 2017 , 82, 46-84	0.7	15
89	Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 197-204	2.1	7
88	Effect of Cis-palmitoleic acid supplementation on inflammation and expression of HNF4 α [HNF4 α] and IL6 in patients with ulcerative colitis. <i>Minerva Gastroenterology</i> , 2017 , 63, 257-263	3	6
87	Interleukin 27 is up-regulated in patients with active inflammatory bowel disease. <i>Immunologic Research</i> , 2016 , 64, 901-7	4.3	13
86	Genetic polymorphisms of interleukin-22 in patients with ulcerative colitis. <i>Revista De Gastroenterología De México</i> , 2016 , 81, 86-90	0.7	3
85	Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. <i>Immunology Letters</i> , 2016 , 172, 79-83	4.1	18
84	Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. <i>Cytokine</i> , 2015 , 75, 389-402	4	56
83	Evaluation of diet pattern related to the symptoms of mexican patients with Ulcerative Colitis (UC): through the validity of a questionnaire. <i>Nutrition Journal</i> , 2015 , 14, 25	4.3	6
82	Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2683-95	4.5	11
81	Frequency, Clinical Features and Factors Associated with Pouchitis after Proctocolectomy with Ileo-Pouch-Anal Anastomosis in Patients with Ulcerative Colitis: A Latin-American Country Retrospective-Cohort Study. <i>Digestive Surgery</i> , 2015 , 32, 489-95	2.5	7
80	Immunoregulatory Pathways Involved in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2188-93	4.5	68
79	Mild clinical behaviour of Crohn disease in elderly patients in a Latin American country: A case-control study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015 , 29, 435-9	2.8	3

78	Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2015 , 2015, 659018	4.3	22
77	Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis. <i>Disease Markers</i> , 2014 , 2014, 932530	3.2	21
76	Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study. <i>Clinical and Experimental Immunology</i> , 2014 , 177, 64-75	6.2	49
75	Association of the interleukin 15 (IL-15) gene polymorphisms with the risk of developing ulcerative colitis in Mexican individuals. <i>Molecular Biology Reports</i> , 2014 , 41, 2171-6	2.8	12
74	High gene expression of CXCL8 is associated with the presence of extraintestinal manifestations and long-term disease in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, E22-3	4.5	6
73	IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis. <i>Journal of Clinical Immunology</i> , 2013 , 33, 640-8	5.7	37
72	Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis. <i>Immunology Letters</i> , 2013 , 149, 50-3	4.1	11
71	Gene and protein expression of centaurin beta 1 (CENTB1) are up-regulated in patients with ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2013 , 7, e238-9	1.5	0
70	Indoleamine 2,3-dioxygenase: expressing cells in inflammatory bowel disease-a cross-sectional study. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 278035		17
69	Interleukins Involved in Inflammatory Bowel Disease as New Therapeutic Targets. <i>Current Immunology Reviews</i> , 2013 , 9, 86-92	1.3	4
68	Reduced expression of mucin 9 (MUC9) in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, E601	4.5	7
67	Differential expression of occludin in patients with ulcerative colitis and healthy controls. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, E1999	4.5	19
66	Gene expression of solute carrier family 9 (sodium/hydrogen exchanger) 3, (SLC9A3) is downregulated in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1197-8	4.5	9
65	Leiden V factor and spastic cerebral palsy in Mexican children. <i>Genetic Testing and Molecular Biomarkers</i> , 2012 , 16, 978-80	1.6	4
64	Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut</i> , 2012 , 61, 706-12	19.2	23
63	Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. <i>Human Immunology</i> , 2011 , 72, 1029-32	2.3	25
62	Interleukin 1 β (IL-1 β) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 531-5	3	38
61	Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. <i>BMC Gastroenterology</i> , 2011 , 11, 138	3	46

60	Peroxisome proliferator-activated receptor-gamma (PPAR- γ) expression is downregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 680-1	4.5	35
59	Increased expression of discs large homolog 5 gene (DLG5) in ulcerative colitis patients compared to healthy individuals. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1639	4.5	1
58	Gene expression of carnitine organic cation transporters 1 and 2 (OCTN) is downregulated in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 2205-6	4.5	9
57	Role of the interleukin 24 in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 2209-10	4.5	6
56	Interleukin-18 upregulation is associated with the use of steroids in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, E50-1	4.5	2
55	Expression of HNF4 α s downregulated in patients with active ulcerative colitis (UC) compared to UC patients in remission and healthy controls. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, E91	4.5	4
54	Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, E135-6	4.5	20
53	Quantification of low expressed SCD1 gene in colonic mucosa from patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, E155	4.5	6
52	HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis. <i>Colorectal Disease</i> , 2010 , 12, 1231-5	2.1	7
51	Prevalence and factors associated with the presence of Abnormal Function Liver Tests in patients with ulcerative colitis. <i>Annals of Hepatology</i> , 2010 , 9, 397-401	3.1	20
50	Intestinal protozoa infections among patients with ulcerative colitis: prevalence and impact on clinical disease course. <i>Digestion</i> , 2010 , 82, 18-23	3.6	58
49	Genetic Susceptibility in Inflammatory Bowel Disease. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010 , 8, 149-159	2.5	
48	Cytomegalovirus infection in patients who required colectomy for toxic megacolon or severe steroid-refractory ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 867-8	4	9
47	High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 541-2	4.5	9
46	Interleukin 21 expression is increased in rectal biopsies from patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1090	4.5	13
45	MDP-NOD2 stimulation induces HNP-1 secretion, which contributes to NOD2 antibacterial function. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 736-42	4.5	22
44	TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1267-8	4.5	15
43	Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1823	4.5	23

42	Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. <i>Annals of Hepatology</i> , 2010 , 9, 397-401	3.1	4
41	Distinguishing between anti-neutrophil cytoplasmic antibody patterns in inflammatory bowel disease: is the "atypical pattern" adding more information?. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1854-5	0.7	8
40	Association of GIST and somatostatinoma in a patient with type-1 neurofibromatosis: is there a common pathway?. <i>American Journal of Gastroenterology</i> , 2009 , 104, 797-9	0.7	13
39	Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility. <i>Saudi Journal of Gastroenterology</i> , 2009 , 15, 208-12	3	6
38	Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1039-43	4.5	17
37	Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006). <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 221-4	3	35
36	Rheumatic manifestations of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009 , 15, 5517-24	5.6	71
35	Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids. <i>Digestive Surgery</i> , 2008 , 25, 383-6	2.5	14
34	New treatment options in the management of IBD - focus on colony stimulating factors. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 501-4	4.4	9
33	Factors that influence outcome in non-invasive and invasive treatment in polycystic liver disease patients. <i>World Journal of Gastroenterology</i> , 2008 , 14, 3195-200	5.6	6
32	Genetic factors associated with the development of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 5594-7	5.6	26
31	Basic and clinical aspects of osteoporosis in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 6156-65	5.6	37
30	HLA-DRB1*08 allele may help to distinguish between type 1 diabetes mellitus and type 2 diabetes mellitus in Mexican children. <i>Pediatric Diabetes</i> , 2007 , 8, 5-10	3.6	5
29	Association of HLA-DRB1*16 with chronic discoid lupus erythematosus in Mexican mestizo patients. <i>Clinical and Experimental Dermatology</i> , 2007 , 32, 435-8	1.8	18
28	HLA-DRB1*0101 is associated with the genetic susceptibility to develop lichen planus in the Mexican Mestizo population. <i>Archives of Dermatological Research</i> , 2007 , 299, 405-7	3.3	11
27	Rheumatoid arthritis associated with pemphigus foliaceus in a patient not taking penicillamine. <i>Skinmed</i> , 2007 , 6, 252-4	0.2	1
26	Basic and clinical aspects of osteoporosis in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 6156	5.6	44
25	Innovative therapeutics for inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 1893-6	5.6	24

24	Novel genetic markers in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 5560-70	5.6	51
23	Innate immunity in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007 , 13, 5577-80	5.6	60
22	Centaurin beta1 down-regulates nucleotide-binding oligomerization domains 1- and 2-dependent NF-kappaB activation. <i>Journal of Biological Chemistry</i> , 2006 , 281, 36060-70	5.4	55
21	Association of HLA-DR3 and HLA-DR4 with sinonasal polyposis in Mexican Mestizos. <i>Otolaryngology - Head and Neck Surgery</i> , 2006 , 135, 90-3	5.5	16
20	Association of the HLA-DRB1*0701 allele with perinuclear anti-neutrophil cytoplasmic antibodies in Mexican patients with severe ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2006 , 12, 1617-20	5.6	6
19	Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution. <i>World Journal of Gastroenterology</i> , 2006 , 12, 3406-9	5.6	7
18	Crohn's disease: innate immunodeficiency?. <i>World Journal of Gastroenterology</i> , 2006 , 12, 6751-5	5.6	27
17	Role of the HLA-DQ locus in the development of chronic gastritis and gastric carcinoma in Mexican patients. <i>World Journal of Gastroenterology</i> , 2006 , 12, 7762-7	5.6	5
16	HLA-DRB1 *04 is associated with the genetic susceptibility to develop vitiligo in Mexican patients with autoimmune thyroid disease. <i>Journal of the American Academy of Dermatology</i> , 2005 , 52, 182-3	4.5	12
15	Association of HLA-DR4 (DRB1*0404) with human papillomavirus infection in patients with focal epithelial hyperplasia. <i>Archives of Dermatology</i> , 2004 , 140, 1227-31		40
14	Polymorphisms in the promoter region of tumor necrosis factor alpha (TNF-alpha) and the HLA-DRB1 locus in Mexican mestizo patients with ulcerative colitis. <i>Immunology Letters</i> , 2004 , 95, 31-5	4.1	31
13	HLA-DRB1 alleles encoding the "shared epitope" are associated with susceptibility to developing rheumatoid arthritis whereas HLA-DRB1 alleles encoding an aspartic acid at position 70 of the beta-chain are protective in Mexican Mestizos. <i>Human Immunology</i> , 2004 , 65, 262-9	2.3	33
12	HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2003 , 10, 707-10	6	17
11	Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. <i>Human Immunology</i> , 2003 , 64, 119-23	2.3	43
10	HLA study on two Mexican Mestizo families with autoimmune thyroid disease. <i>Autoimmunity</i> , 2002 , 35, 265-9	3	9
9	Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with systemic lupus erythematosus (SLE). <i>Genes and Immunity</i> , 2001 , 2, 363-6	4.4	69
8	Haplotype distribution of class II MHC genes in Mexican patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 1998 , 27, 373-6	1.9	32
7	Complotype SC30 is associated with susceptibility to develop ulcerative colitis in Mexicans. <i>Journal of Clinical Gastroenterology</i> , 1998 , 27, 178-9	3	13

6	HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA). <i>Journal of Autoimmunity</i> , 1997 , 10, 579-83	15.5	18
5	Further evidence of the role of HLA-DR4 in the genetic susceptibility to actinic prurigo. <i>Journal of the American Academy of Dermatology</i> , 1997 , 36, 935-7	4.5	54
4	Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the State of Guerrero, Mexico. <i>Mycopathologia</i> , 1997 , 138, 137-42	2.9	21
3	Independent Associations of the HLA-B27 Antigen and the Complement Haplotype SC21 in Chronic Anterior Uveitis. <i>Ocular Immunology and Inflammation</i> , 1996 , 4, 203-6	2.8	
2	HLA-DR6 (possibly DRB1*1301) is associated with susceptibility to Takayasu arteritis in Mexicans. <i>Heart and Vessels</i> , 1996 , 11, 277-80	2.1	24
1	Diagnostic Delay of Inflammatory Bowel Disease Is Significantly Higher in Public versus Private Health Care System in Mexican Patients. <i>Inflammatory Intestinal Diseases</i> , 1-9	2.5	